TB-500 Side Effects: Incidence Rates Across Trials
A clinical review of TB-500 (thymosin beta-4 active fragment) adverse event rates drawn from human trials, FAERS reports, and post-market literature. prepared by the HealthRX.com Editorial Team.
3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
A clinical review of TB-500 (thymosin beta-4 active fragment) adverse event rates drawn from human trials, FAERS reports, and post-market literature. prepared by the HealthRX.com Editorial Team.
A clinical review of rare and serious adverse events linked to TB-500 (thymosin beta-4 active fragment), including oncologic risk, cardiovascular signals, immunologic effects, and what the current evidence actually shows.
A clinical review of TB-500 (thymosin beta-4 active fragment) withdrawal and discontinuation syndrome, adverse events, and what to expect when stopping this research peptide.

LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.